Dr. Yue Han 韩玥
Chief Physician
Department of Interventional Therapy, Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional ablation therapy for primary liver cancer and liver metastases.
Dr. Han holds a PhD in Surgery from Xi'an Medical University (2004) and has worked at this hospital since graduation. The doctor performs ultrasound- and CT-guided radiofrequency and microwave ablation for liver, lung, and adrenal tumors, with over 1,000 cases. Dr. Han serves as an instructor for national standardized training on tumor ablation technology organized by the National Health Commission and the Chinese Medical Doctor Association.
Professional roles
- Editor-in-Chief, Electronic Journal of Liver Cancer
- Vice Chair, Liver Cancer Minimally Invasive Comprehensive Treatment Branch, Tumor Minimally Invasive Treatment Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Han Yue). Papers usually list the name as Yue Han or Han Y.
Selected publications
44 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Cancer Res Clin Oncol, 2026 (senior author): Efficacy and safety of transarterial chemoembolization (TACE) with tislelizumab and tyrosine kinase inhibitors versus TACE for intermediate and advanced HCC. PubMed 42287455
- World J Clin Oncol, 2025 (senior author): Long-term outcomes of thermal ablation vs surgical resection for single small hepatocellular carcinoma. PubMed 41355922
- Front Oncol, 2024 (senior author): Effectiveness and safety of vascular intervention plus lenvatinib versus vascular intervention alone for hepatocellular carcinoma patients with portal vein tumor thrombus: a retrospective comparative study. PubMed 39035736
- J Cancer Res Ther, 2022 (senior author): Delayed biopsy following completion of transarterial chemoembolization in patients with hepatocellular carcinoma: Effects on pathological outcomes and its advantages. PubMed 36204882
- Front Oncol, 2022 (first author): Long-term outcome following microwave ablation of lung metastases from colorectal cancer. PubMed 35936731
- BMC Gastroenterol, 2021 (first author): Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study. PubMed 34670512
- World J Gastroenterol, 2021 (first author): Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PubMed 34040331
- Mol Cell Biochem, 2018 (first author): Negative regulation of MAVS-mediated innate immune response by ASC. PubMed 29280086
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion